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To Behrouz and Nova 
                                  & 
     To those who do not surrender in difficulties
"I don't have any particular recipe . . . Doing research is challenging as well as 
attractive. It is like being lost in a jungle and trying to use all the knowledge that 
you can gather to come up with some new tricks, and with some luck you might 
find a way out."
Maryam Mirzakhani, The First Woman To Win Math's Most Prestigious Prize, 
Field's Medal 2014
ABSTRACT
The overall aim of this thesis was to assess the role of biomarkers in chronic 
inflammatory disease. The goal of the first study was to investigate the associa-
tion of sIL-6R and sgp130 levels and risk of first myocardial infarction (MI), and 
to explore the potential interaction between these two biomarkers in association 
with risk of MI. 
In the second study, the aim was to identify genetic loci associated with the circu-
lation of sgp130, known as an inhibitor of the IL-6 trans-signaling, and also to test 
the association between the single nucleotide polymorphisms (SNPs) associated 
with sgp130 and carotid intima-media thickness (c-IMT) as a surrogate marker 
of atherosclerosis. 
The main objective of the third study was to investigate whether environmental 
risk factors of rheumatoid arthritis (RA) affect the occurrence of different reac-
tivity patterns to citrullinated peptides and the presence of rheumatoid factor (RF) 
isotypes.
Study I was carried out in the Stockholm Heart Epidemiology Program (SHEEP), 
a case-control study designed to determine new risk factors. sIL-6R and sgp130 
levels were measured in serum of 682 and 664 MI cases and 1103 and 1062 con-
trols, respectively. Increased concentrations of sIL6R were associated with a high 
occurrence of MI while very high levels of sgp130 had an inverse association 
with incidence of MI. The obtained results indicated presence of an interaction 
between the low level of sgp130 and the high level of sIL6R that might have a 
synergistic effect on increased risk of MI. Our results highlighted the necessity of 
focusing on molecular pathways instead of only one biomarker when estimating 
the risk of CVDs.
Study II was performed in IMPROVE, a European multicenter prospective study 
recruited subjects with high risk profile for cardiovascular diseases. c-IMT  was 
measured at baseline and after 30 months follow-up. Genomic DNA of 3703 par-
ticipants was genotyped using the CardioMetaboChip and ImmunoChip. A linear 
regression model was used to assess the association of 360,842 SNPs and sgp130 
levels. Model was adjusted for gender, age and population structure. rs10935473 
and rs1929666, located at chromosome 3 and 10 respectively, had an association 
with sgp130 circulation. Besides, 24 SNPs showed the suggestive association 
with sgp130 levels. A positive association between rs17688225 and serum level of 
sgp130 was observed while this SNP showed a negative association with c-IMT. 
Our results indicated that sgp130 levels is regulated by multiple genetic loci, which 
is likely these loci partly also regulate c-IMT measures.
In study III, analyses were based on data from two Swedish RA patients cohorts: 
Epidemiological Investigation of RA (EIRA, n=2859), and early RA from Umeå 
(eRA-Umeå, n=1011). Our results corroborate the wide-spread co-occurrence of 
different RA-specific antibodies, which is likely mediated by epitope spreading 
or cross-reactivity. When analyzing all antibodies jointly, we found that smoking 
is mainly associated with the presence of anti-Cit-Fibα36-50, anti-CEP-1 as well 
as with IgA-RF. No conclusive associations were found between low alcohol 
consumption or high BMI with the presence of any specific autoantibody. Our 
study indicated smoking might play a part in pathogenesis of RA through specific 
anticitrulline immunity by increasing the exposure of these antigens in affected 
tissues like lungs. 
SAMMANFATTNING PÅ SVENSKA
Det övergripande syftet med denna avhandling var att utvärdera biomarkörernas roll 
i kronisk inflammatorisk sjukdom. Målet med den första studien var att undersöka 
sambandet mellan sIL-6R- och sgp130-nivåerna och risken för en första episod 
av hjärtinfarkt, samt undersöka den potentiella interaktionen mellan dessa två 
biomarkörer i risk för hjärtinfarkt. I den andra studien syftade vi till att identifiera 
genetiska varianter kopplade till sgp130-serumnivåer, den naturliga antagonisten 
mot IL6-transignaleringen. Vi undersökte även sambandet mellan genotyperna 
förknippade med sgp130 och en markör för subklinisk åderförkalkning (carotis 
intima-media tjocklek, c-IMT). Målet med den tredje studien var att undersöka om 
miljöfaktorer för reumatoid artrit (RA) påverkar förekomsten av sjukdomsspeci-
fika antikropparna mot citrullerade peptider och reumatoid faktor (RF) isotyper.
Studie I genomfördes i en stor befolkningsbaserad fallkontrollstudie, Stockholm 
Heart Epidemiology Program (SHEEP). Vi mätte nivåer av sIL6R och sgp130 i 
serumprover från 682 respektive 664 hjärtinfarktspatienter, och 1103 respektive 
1062 kontroller. Förhöjda koncentrationer av sIL6R var förknippade med en ökad 
förekomst av hjärtinfarkt och mycket höga nivåer av sgp130 var associerade med 
en reducerad förekomst av hjärtinfarkt. Våra resultat indikerar även en interaktion 
mellan dessa två biomarkörer, som föreslår att låga sgp130-nivåer tillsammans 
med höga sIL6R-nivåer öka risken för hjärtinfarkt mer än förväntat. 
Studie II utfördes i IMPROVE, en europeisk prospektiv multicenterstudie utformad 
för att undersöka sambandet mellan c-IMT och c-IMT-progression med risken för 
framtida kardiovaskulära sjukdomar. Genomiskt DNA genotypades med hjälp av 
CardioMetaboChip och ImmunoChip. rs10935473 (på kromosom 3) och rs1929666 
(på kromosom 10) var signifikant förknippade med sgp130-nivåer och 24 genetiska 
varianter visade svagare association med sgp130-nivåer. En av de genetiska vari-
anterna med svagare association, rs17688225 på kromosom 14, visade en negativ 
association med c-IMT. Våra resultat indikerar att sgp130-nivåerna regleras av 
flera genetiska varianter som till viss del överlappar dem som reglerar c-IMT. 
Studie III använde data från två svenska kohorter av RA-patienter: Epidemiologisk 
undersökning av RA (EIRA, n = 2859) och tidig RA från Umeå (eRA-Umeå, n = 
1011). Våra resultat bekräftar att patienter oftast utrycker flera olika antikroppar 
som binder flera olika auto-antigen samtidigt. Detta medieras troligen av epitop-
spridning eller korsreaktivitet. När vi analyserade alla antikroppar gemensamt 
fann vi att rökning huvudsakligen är förknippat med närvaron av anti-Cit-Fibα36-50, 
anti-CEP-1 såväl som med IgA-RF. Vi hittade inga tydliga samband mellan låg 
alkoholkonsumtion eller hög BMI med närvaron av någon specifik autoantikropp.
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11 BACKGROUND 
Inflammation is a self-protection reaction of the body in response to the harmful 
stimuli like pathogens, if inflammation progress to a chronic state, this may cause 
diseases, such as atherosclerosis or rheumatoid arthritis (RA). The focus of this 
thesis was on inflammatory biomarkers and two chronic inflammatory diseases: 
cardiovascular diseases (CVDs), particularly Myocardial Infarction (MI) and 
atherosclerosis, as well as RA. 
A biomarker usually imputes to a distinct biological indicator such as measurable 
molecules in bodily fluids and can be used to assess both normal or pathogenic 
processes and evaluation of treatment responses. To be more specific, the risk 
or progression of a disease or the effect of a given treatment for a disease can 
be evaluated by relevant biomarkers, such as changes in expression or state of 
a protein. They can also be used to infer the genetic causes of diseases (1). For 
instance, the presence of autoantibodies in the serum of patients in a very early 
stage of the disease is a typical biomarker of autoimmune diseases. Autoantibodies 
as biomarkers can help the clinicians to diagnose the disease at an earlier stage 
and also classify the patient and provide adequate medications.
1.1 CVD
CVDs are of interest for researchers because they are the primary source of  mortality 
in the world. The World Health Organization (WHO) estimates that CVDs will 
be the leading cause of death in all continents apart from Africa until 2030 and 
therefore remain a center of attention within the field. The 2016 Global Burden of 
Disease reported 31% of all deaths globally (17.9 million), as attributed to CVD (2).
Based on European CVD statistics 2016, despite all the development in diagnosis 
and treatment of CVDs, still more than 4 million deaths occur every year due to 
CVD across the continent (3). According to the WHO, CVDs are defined as a class 
of disorders that involve heart and blood vessels and include (4):
1) Coronary Heart Disease (CHD)
2) Cerebrovascular diseases
3) Peripheral arterial disease
4) Congenital heart disease
5) Rheumatic heart disease
6) Deep vein thrombosis
7) Pulmonary embolisms
2Risk factors contributing in the development of CVDs can be categorized as: 
1) Modifiable risk factors: i.e. hypertension, smoking, raise blood glucose (dia-
betes), lack of physical activity, unhealthy nutritional habits, hyperlipidemia, 
being overweight and obese. These risk factors can be controlled or treated, 
that in turn prevents CVDs and reduces the number of deaths each year caused 
by CVDs. 
2) Non-modifiable risk factors: i.e. age, gender and family history of CVD. These 
actualities cannot be changed, however regular checkups for high-risk groups 
of individuals is recommended (5).
1.1.1 CHD
CHD is the most common type of CVD. Alternative titles for CHD are coronary 
artery disease (CAD), ischemic heart disease and atherosclerotic heart disease. 
CHD consists of stable angina, unstable angina, MI and sudden cardiac death. 
These are the clinical manifestation of atherosclerosis, a chronic inflammatory 
disease of the coronary arteries. 
Despite the importance of common risk factors for the onset of cardiovascular 
events (CVEs), it is commonly suggested that more than 50% of patients suffer 
from CHD have none of the traditional cardiovascular (CV) risk factors (6). This 
implies that other nontraditional risk factors have a significant role in the develop-
ment of CHD. Therefore, it is essential to investigate the non-conventional risk 
factors and new biomarkers in addition to traditional risk factors to predict CHD 
and consequently CVDs. This would enhance the chance of preventing the disease 
onset and thereby reducing CVDs mortality.
1.1.1.1 MI
MIs usually occur due to acute ischemia in myocardium where thrombus blocking 
the coronary arteries. Artery occlusion happens because of stenosis of the coronary 
artery by an atherosclerotic plaque that causes acute ischemia, lack of blood flow to 
the myocardium, which in turn leads to oxygen deprivation in the cardiac muscles.
The definition of MI has developed gradually with the increase in sensitivity and 
specificity of available biomarkers. The universal definition of MI was originally 
published in 2007 (19). According to the international task force, the updated uni-
versal definition for MI (from 2014 (20)) concentrates on clinical criteria as well 
as biomarkers and consist of electrocardiogram changes and imaging. Acute MI 
is defined as myocardial cell death in response to extended myocardial ischemia.
31.1.1.2 Atherosclerosis
Atherosclerosis is a chronic and progressive inflammatory disease of the blood 
vessel wall and represents the biological lesion underlying atherosclerosis-related 
CVDs. The clinical manifestations of atherosclerosis are specific for different vas-
cular beds and are related to the stability of focal atherosclerotic lesions, called 
plaque. Plaques usually contain loads of lipids, including cholesterol and fatty 
acids and white blood cells, particularly macrophages (7). 
If atherosclerotic plaque forms in the coronary arteries, it is more likely to grow 
within the vascular wall and reducing the blood flow in cardiac tissue and conse-
quently, facilitate the onset of chronic ischemia. Atherosclerotic lesions are cat-
egorized as stable or unstable (vulnerable) plaques. Stability of an atherosclerotic 
plaque is more important than its size and depends on its cellular and extracellular 
contents. 
Stable plaques are characterized by a thick fibrous cap, small lipid cores, few 
inflammatory cells and many smooth muscle cells. Stable plaques usually result 
in clinical symptoms described as stable angina. At the other side of the spectrum 
are atherosclerotic plaques in the coronary arteries, which are characterized by 
large lipid cores, high inflammatory content (numerous macrophages) and pro-
angiogenic activities. These are called unstable plaques. They have relatively few 
smooth muscle cells and a very thin fibrous cap that tends to rupture in response 
to different stimuli (8, 9).
When the cap rupture, is followed by activation of the coagulation cascade and 
thrombus formation. Existing platelets and coagulation factors in blood circulation 
will be faced by the plaque’s extracellular matrix and lipid core that has thrombo-
genic characteristics. Afterwards, the disrupted plaque is used as scaffolding for 
platelet aggregation and coagulation, eventually thrombus formation. 
Thrombus size depends on the plaque rupture area. When it is large enough, the 
thrombus can occlude the coronary vessel lumen. The blockage can be either partial 
or complete, thereby accelerate the occurrence of an acute coronary event. The 
clinical manifestation of plaque rupture or superficial erosion is often MI (10, 11).
Atherosclerosis might remain subclinical during years, which indicates the require-
ment of different methods to identify the presence of atherosclerosis. Available 
techniques such as intravascular ultrasonography and B-mode ultrasonography 
are used to measure the surrogate markers of atherosclerosis. According to the 
estimations, the different dosage of statin treatment can be prescribed to reduce, 
cease or even inverse the progression of atherosclerotic disease (12).
4Atherosclerosis and inflammation
Several lines of evidence indicated the key role of inflammation in all phase of 
atherosclerosis. Various cytokines like IL-12, IL-6, IL-1, IL-2, IL-8, IL-10, IL-17, 
tumor necrosis factor α (TNF-α), and C-reactive protein (CRP) are associated with 
CVDs and involved in the inflammatory processes contributing to atherosclerosis 
and plaque formation in the vessel walls of human (13). However, the independent 
contribution of inflammatory biomarkers to the risk of CVD is still not fully known.
Subclinical atherosclerosis 
Carotid intima-media thickness (c-IMT) is a surrogate marker for early athero-
sclerosis that reflects the extension of the thickness of the intima-media layer in 
carotid artery. c-IMT is used as an intermediate phenotype for diagnosis of early 
stages of atherosclerosis. Several large population-based studies have indicated 
c-IMT as a valid estimation of the risk for CVEs (14).
Based on the results of different epidemiological studies, c-IMT is associated 
with various CV risk factors like diabetes and impaired glucose tolerance, hyper-
cholesterolemia (15, 16), high-density lipoprotein cholesterol and triglycerides (17). 
Using c-IMT as a biomarker of CVD is beneficial because it is a non-invasive, 
un-complicated and a low-cost method. Moreover, it is reproducible and radiation-
free. This test can classify individuals as high or low risk groups for CVDs, and 
appropriate precautionary action plans can be implemented accordingly (12).
c-IMT usually is measured in far and near walls of four segments of both right 
and left carotid arteries: at the internal carotid arteries, at the carotid bifurcation, 
in the 1st cm of the common carotid, in the proximal artery (18).
Differences in c-IMT in different parts of the artery can reflect the variation in the 
local hemodynamic forces. Usually, c-IMT measurement of the deeper wall (far 
wall) is more reliable for diagnosis of atherosclerosis compared to the adjacent 
wall and is thus the most applied in clinical studies. 
Based on guidelines presented jointly by European society of hypertension and 
European society of cardiology, the normal values for c-IMT is <0.9 mm, and c-IMT 
value between 0.9 mm and 1.5 mm is an indication of atherosclerosis and high 
risk of CVD. c-IMT values >1.5 mm demonstrate asymptomatic carotid plaque. 
Changes in c-IMT can reflect regression and or progression of atherosclerotic 
CVD (18). If the increased in c-IMT is detected in the early stage, there is a pos-
sibility of prevention or treatment before more serious damage to the vessel wall.
51.2 BIOMARKERS FOR CVDS 
1.2.1 IL-6
IL-6 is a 26-kDa inflammatory cytokine with a four-helix bundle structure and 
consists of 184 amino acids (21). IL-6 is a pleiotropic cytokine that has pro-inflam-
matory as well as anti-inflammatory characters. This key cytokine has different 
effects on the immune system, liver, the endothelium and the vascular smooth 
cells. IL-6 influences the accumulation of platelets and proliferation of vascular 
smooth muscle cells in coronary arteries (22). In hepatocytes, IL-6 regulates the 
production and the release of the acute-phase proteins, for instance, CRP (23). 
In endothelial cells, IL-6 has a regulatory effect on the expression of adhesion 
molecules as well as other cytokines such as IL-1β and TNF-α. The secretion of 
these cytokines, along with IL-6 from endothelial cells creates a microenvironment 
that facilitates the initiation of an inflammatory process in the vessel wall. This 
represents one of the central mechanisms involved in the onset and progression 
of atherosclerosis (24).
1.2.2  IL-6R, sIL-6R, gp130 (Biology of IL-6 inflammatory 
signaling pathways)
IL-6 mediates its biological activities by binding to two membrane proteins: an 
80-kDa glycoprotein called IL-6 Receptor (IL-6R) and a 130-kDa trans-membrane 
signal transducer protein named glycoprotein130 (gp130). IL-6R is expressed on 
leukocytes, monocytes and hepatocytes, where it regulates the release of acute-phase 
proteins and inflammatory cytokines (25). The soluble form of IL-6R (sIL-6R) is 
present in serum (ng/ml) and is a 50-55 kDa protein lacking the trans-membrane 
and cytoplasmic regions of IL-6R. sIL-6R is produced either by limited proteolytic 
shedding of the membrane-bound receptor or by translation from alternatively 
spliced mRNA (26) (Figure 2).
The IL-6 signaling pathway that is activated in the presence of membrane bound 
IL-6 receptor is called classic-signaling, which mostly regulate the beneficial 
regenerative and anti-bacterial roles of IL-6. The alternative signaling pathway 
that is mediated by soluble IL-6R is known as trans-signaling. It is suggested that 
trans-signaling is accounted for the majority of the detrimental IL-6 effects (27). 
In both signaling pathways, IL-6/IL-6R or IL-6/sIL-6R complex is followed by 
the homodimerization of gp130 subunits that are naturally expressed on all cell 
types. Thereafter the intercellular signaling cascade is initiated (Figure 1).
6gp130 has no measurable affinity for IL-6 or IL-6R alone, but a high affinity for 
both IL-6/IL-6R and IL-6/sIL-6R complexes. Therefore, all cells that have gp130 
present in their membranes can be responsive to IL-6, even in the absence of IL-6R, 
by the complex of IL-6 and sIL-6R (28). 
1.2.3 sgp130
A soluble form of gp130 (sgp130) exists in human blood in three isoforms (50-
110kDa); sgp130-RAPS, sgp130-E10 and full-length sgp130 (29-31). They are 
produced by proteolytic cleavage of gp130 and or alternative splicing of mRNA 
encoding the transmembrane protein (32). sgp130 represents a natural antagonist 
of the IL-6/sIL-6R pathway (33). sgp130 inhibits the trans-signaling through 
specific binding to the IL-6/sIL-6R complex with a high affinity (1mM). IL-6/
sIL-6R complex coordinates the pro-inflammatory and the proatherogenic effects 
of IL-6 through trans-signaling (34, 35) and based on several animal and in vitro 
studies sgp130 circulation can prevent its binding to the membrane-bound gp130 
and block the signaling pathway (36, 37) (Figure 2). In other words, sgp130 can 
behave as an anti-inflammatory factor by inhibiting inflammatory trans-signaling 
pathway and have a beneficial effect on inflammatory diseases and atherosclerosis, 
Figure 1. IL-6 classic-signaling pathway through IL-6R (left panel) and trans-signaling 
pathway through sIL-6R (right panel).
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7thus can be an ideal pharmacological target for IL-6 signaling cause inflamma-
tory conditions. According to an in-vitro study, sgp130 play an inhibitory role 
for IL-6 trans-signaling mostly in the full-length isoform (38). Note that it is not 
possible to recognize which isoform of sgp130 is detected by biological assays. 
The potential therapeutic application of sgp130 to prevent CVDs is of interest for 
several research institutions.
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Figure 2. The IL-6 signaling pathways: soluble forms of IL-6R and gp130 are produced 
by proteolytic cleavage (A) and or alternative splicing (B) of the full-length membrane-
bound forms. The pro-inflammatory effect of IL-6 occurs through trans-signaling (C) 
and sgp130 can inhibit the trans-signaling (D).
1.3 IL-6, SIL-6R, SGP130 AND RISK OF CVDS 
IL-6 is a known and independent risk indicator of various CVDs. In particular, 
increased serum level of IL-6 is associated with elevated MI risk (39). One pro-
spective study of MI showed men with high IL-6 plasma levels had 2.3 times 
higher risk of developing MI compare to those with low levels, still significant 
after adjusting for traditional CV risk factors (40). Moreover, results from two 
recent genetic meta-analyses of >200 000 subjects suggested a causal relationship 
between IL-6 signaling and coronary heart disease (41).
8sIL-6R seems to mediate the inflammatory effects of IL-6 via trans-signaling 
(42) (Figure 3). The role of IL-6 trans-signaling pathway (through IL-6/sIL-6R 
complex) has been emphasized in retaining chronic inflammation in systemic dis-
eases like atherosclerosis (43). In a case-control study, patients with MI and CHD 
showed an elevated level of sIL-6R compared to controls, in the same population 
no difference in level of sgp130 was observed in cases and controls (44, 45). In 
other studies of the heart failure, an increased level of sgp130 has been reported 
in patients (46-48). The causal effect of IL-6 trans-signaling on development of 
atherosclerosis, as a key cause of CVDs, has been investigated by different clini-
cal (49) and experimental studies (50, 51). 
It has been studied if blocking IL-6 trans-signaling can prevent the inflammatory 
effects of IL-6 in different diseases. In this regard, a recombinant form of sgp130 
(sgp130Fc) has been applied as IL-6 trans-signaling inhibitor in several inflam-
matory and degenerative disease models in the animal and in-vitro studies (52, 
53). An experimental research performed on a mouse model indicated that the 
administration of sgp130Fc has a significant protective effect on athero sclerosis. 
It showed that sgp130 reduced the atherosclerotic plaque development and pro-
gression through nullifying the IL-6/sIL-6R trans-signaling (50). This suggests 
that sgp130 may antagonize the effect of IL-6/sIL-6R complex on the progression 
of atherosclerotic lesions. sgp130Fc is in fact now tested as an anti-inflammatory 
drug in phase 1 clinical trials for rheumatoid arthritis (54).
1.3.1 sgp130 genetic variants and risk of CVD
Genetic and environmental factors together define if an individual is susceptible 
to CVD. Genome Wide Association Study (GWAS) have provided a platform to 
explore the association between specific genetic variants and diseases.
The genes which regulate the level of sgp130 mainly have not been discovered 
yet. The association of polymorphisms in the gp130 gene with CVD risk has 
been investigated in a few studies. One single nucleotid polymorphism (SNP) 
(rs3729960) in GP130 at chromosome five is associated with a decline in the risk 
of MI, independently of other conventional CV risk factors (55). Furthermore, one 
study on two separate population, 546 subjects from OSLO high-risk population 
for CAD and 299 subjects from VIENA population with angiographically proven 
CAD, demonstrated a higher level of sgp130 in the individuals carrying the gp130 
polymorphism G148C in comparison with wild type (56). 
Increasing the knowledge on genetic variants regulating sgp130 is important, to 
understand the mechanisms underlying generation of sgp130 as an inhibitor of IL-6 
trans-signaling and as a potential therapeutic marker in inflammatory diseases.
91.4 C-IMT AND INFLAMMATORY BIOMARKERS 
Research on the association between inflammatory biomarkers and c-IMT as an 
indicator of CVD is essential for more precise risk prediction of CVDs as well as for 
effective prevention and treatment of atherosclerosis. Some previous studies have 
shown the association between c-IMT and inflammatory biomarkers. Wang et al. 
have indicated the association between c-IMT and CRP in women (57). Furthermore, 
an independent positive association between IL-6 level and c-IMT has been reported 
in patients with growth hormone deficiency who are at higher risk of CVDs (58). 
Moreover, results from one study in patients with obstructive sleep apnea has shown 
significant correlation between c-IMT and CRP, IL-6 and IL-18 serum levels. This 
proposes an association between systemic inflammatory biomarkers and elevated 
risk of atherosclerosis progression, thus increasing the risk of CVDs in patients 
with obstructive sleep apnea (59). Another finding from an epidemiological study 
with individuals at risk of CVDs (having at least three different traditional CV risk 
factors) showed an inverse association between the plasma IL-5 concentration and 
changes in c-IMT over 30 months follow-up in women (60). 
1.5 RA
RA is the most common chronic inflammatory autoimmune disease, and a conse-
quence of the faulty attacks of the immune system to the body tissue, specifically 
synovial tissue. The result is inflammation and stiffness of the joint linings, and 
unless successfully treated, it leads to bone erosion and loss. RA initially affects 
the wrist and small joints of the hands, such as middle joints of the fingers, and 
typically leads to painful and swollen joints (61). The disease involves  symmetric 
pattern in pain, stiffness and swelling in peripheral joints on both sides of the 
body. Other symptoms such as fever, fatigue or low energy and reduced appetite 
can appear gradually. It can take weeks and months to verified diagnosis (62-64). 
The inflammation might expand to other parts of the body like lungs, heart, eyes 
and nerves. The cause of RA, like other autoimmune diseases is complex and 
involving both genetic and environmental factors (65). RA can appear in any age, 
but its incidence rate increases with age (up to age 55-80) and women have 2.5-3 
times higher risk. It is estimated that RA affects nearly 0.5-1% of the whole popu-
lation of the world (66). According to data from nationwide register-based study 
and Swedish Rheumatology Quality register in Sweden, RA incidence is 41 per 
100,000 (67, 68). Various inflammatory cytokines like IL-6, TNF-α and IL-1 are 
highly expressed in RA. TNF-α is the main cytokine causing inflammation in the 
synovium of RA patients. Increased level of IL-6 is measurable in synovial fluids 
of RA patients with high disease activity. Synovial membrane express IL-6, and 
there is a correlation between the level of IL-6 and the level of radiological joint 
damage. Tocilizumab is used as a medication against the IL-6 receptor and inhibits 
the IL-6 trans-signaling and inflammatory effect of IL-6.
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1.6 BIOMARKERS FOR RA
1.6.1 Rheumatoid factor (RF)
RF is an autoantibody that was originally found in RA patients. IgM-RFs are the 
most observed isotype, but IgA, IgG, IgE, IgD RFs may also be detected. RFs 
have been reported in other autoimmune and non-autoimmune diseases as well as 
in healthy individuals (69). The RF test has high sensitivity but low specificity for 
RA. RF is detected in about 75% of the RA patients, but it is also present in other 
autoimmune diseases and infectious diseases. Positive RF test is not sufficient for 
RA diagnosis but aids diagnosis. For being classified as a RA patient according to 
the 1987 American College of Rheumatology (ACR), the patients must fulfill at 
least four of seven criteria (Table 1), where RF positivity is one criterion. 
Table 1. The 1987 revised criteria for the classification of RA* 
The 1987 revised criteria for the classification of RA*
1.Morning stiffness
2. Arthritis of 3 or more joint areas
3. Arthritis of hand joints
4. Symmetric arthritis
5. Rheumatoid nodules
6. Serum rheumatoid factor
7. Radiographic changes 
* The patients must have at least 4 of these 7 criteria to be classified as RA case
Source: The American Rheumatism Association 1987 revised criteria for the classification 
of rheumatoid arthritis (70)
1.6.2 Anti-citrullinated protein/peptide antibodies (ACPAs)
Citrullination is a posttranslational protein modification where the  unusual amino 
acid citrulline substitutes an arginine. Calcium-dependent peptidyl  arginine deimi-
nase (PAD) is an evolutionarily conserved protein that catalyzes the citrullination 
of proteins. Several isoforms for PAD are known in human (PAD1–4 and PAD6). 
PAD can citrullinate the extracellular proteins such as collagen and fibrinogen in 
tissues under inflammatory conditions (71). 
Antibodies directed against citrullinated peptides are RA specific (72-74). They 
are routinely measurable using an anti-cyclic citrullinated peptide (anti-CCP) 
test. The recent generation of CCP (CCP-2) test is an ELISA based assay that 
captures reactivity towards either in vitro or synthetic citrullinated peptides. It is 
more discriminative than RF test, since it has RF-like sensitivity along with high 
specificity for RA. Around 40% of RF-negative patients with RA are positive for 
the anti-CCP test. 
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ACPAs are predictive marker used by clinicians for early RA diagnosis. The updated 
diagnostic criteria from 2010 from ACR and EULAR are shown in Table 2 (72). It 
is more likely that RF positive patients are also ACPA positive. Since anti-citrulline 
immunity and RF autoantibodies are expressed even years before the onset of any 
symptoms, it is believed that they are involved in the early process of joint destruction 
and the pathogenesis of RA. 
Data from a longitudinal study showed that 75% of 318 undifferentiated inflam-
matory arthritis subjects with anti-CCP positive at baseline have classified as RA 
patients after one-year follow-up. This number increased to 93% after three years of 
follow-up. Meanwhile, only 25% of anti-CCP negative individuals had progressed to 
RA after three years. A similar study of 314 early RA patients reported that 90% of 
anti-CCP positive participants were classified as RA after one-year follow-up (75). 
This emphasizes on prognostic characteristics of anti-CCP antibodies as a biomarker 
for RA and can help patients to be prioritized for treatment.
Importantly, different RA patients display reactivity towards different specific citrul-
linated peptides (65, 76). Commercial CCP-2 tests are meant to identify any reac tivity 
towards citrullinated peptides, but they do not specify which certain citrullinated 
peptides that the individual has reactivity against.
Table 2. The 2010 ACR/EULAR criteria for the classification of RA. ESR: Erythrocyte 
sedimentation rate.
Classification criteria for RA (score-based algorithm: add scores of  categories A-D: 
a score of ≥6/10 is needed for classification of a patient as having definite RA
Score
A. Joint involvement 
1 large joint 
2-10 large joints 
1-3 small joints (with or without involvement of large joints) 
4-10 small joints (with or without involvement of large joints) 
>10 joints (at least 1 small joint) 
0
1 
2 
3 
5
B. Serology (at least 1 result is needed for classification) 
Negative RF and negative ACPA 
Low-positive RF or low-positive ACPA 
High-positive RF or high-positive ACPA 
0
2 
3
C. Acute phase reactants (at least 1 test result is needed for classification) 
Normal CRP and normal ESR 
Abnormal CRP or abnormal ESR 
0 
1
D. Duration of symptoms 
<6 weeks 
≥6 weeks
0
1
Source: 2010 Rheumatoid arthritis classification criteria: an American College of 
Rheumatology/European League Against Rheumatism collaborative initiative (77)
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Recently a new multiplexed array has been developed that simultaneously captures 
reactivity towards multiple citrullinated antigens. This array includes more than 
40 citrullinated autoantigens that were subdivided according to their “protein of 
origin”. Table 3 summarizes the citrullinated peptide antigens on the multi plex 
chip array. Citrullinated peptide antigens on the multiplex microarray were named 
based on their protein source and the location of amino acid in the peptide chain 
that arginine residue was substituted by citrulline residue.
Table 3. Citrullinated peptide antigens on the multiplex microarray.
Protein source Citrullinated Peptide
Fibrinogen cit-Fibß36-52, cit-Fibα563-583, cit-Fibα580-600, cit-Fibα621-635, cit-Fibα36-50,  
cit-Fibß60-74, cit-Fibßcit-R, cit-FibßR-cit, CCP-1
Vimentin cit-Vim60-75, cit-Vim2-17
α-enolase CEP-1
Collagen type II cit-C1, cit-F4R-cit, cit-F4cit-cit, cit-F4cit-R
filaggrin CCP-1
hnRNP A3 cit-Pept-Z1, cit-Pept-Z2, cit-Pept-1, cit-Pept-5, cit-Pept-Bla26
Peptides on the array included in study III derived from:
1) vimentin, which is fibroblast intermediate filament found in the cytoskeleton 
in eukaryotic cells and present in around two-third of RA patients (78). 
2) fibrinogen is a hexameric plasma glycoprotein central to coagulation. Around 
50-60% of RA patients have immune reactivity towards citrullinated fibrinogen 
epitopes (79). 
3) alpha-Enolase (α-Enolase): is a ubiquitously expressed glycolytic enzyme. 
Around 40% of RA patients express antibody against citrullinated-peptide 
epitope CEP-1, which is an immunodominant epitope in this group of peptides 
(80). 
4) collagen type II are the triple-helical peptides that are the main component of 
hyaline cartilage. Anti-citrullinated collagen type II antibodies are found in 
about 40% of patients with RA (81).
5) filaggrin is a filament-associated protein that attaches to keratin fibers, mostly 
found in epithelial cells.
6) Heterogeneous Ribonuclear Protein A3 (hnRNP A3).
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The presence of processes like cross-reactivity and epitope spreading among ACPA 
are widely known, which contribute to the co-occurrence of these RA specific 
citrullinated peptide antibodies. (82, 83). 
The ability of an antibody to react with a similar epitope on different antigens 
call cross-reactivity. Some of the antibodies towards citrullinated peptides may 
react to more specific citrullinated antigens, but most of them tend to be widely 
cross-reactive (82, 83). 
Epitope spreading is characterized as the development of immunity against diverse 
epitopes. This immune response can be directed towards a self or foreign antigen, 
to subdominant epitopes on that protein instead of the immunity reactivity against 
dominant specific epitope (84, 85). Co-occurrence of ACPAs from epidemiological 
aspect can be translated to mediating or colliding effect, meaning each antibody 
can mediate the presence of another antibody.
1.7 ENVIRONMENTAL RISK FACTORS FOR RA
Environmental factors can play an essential role in the origination of systemic 
inflammation and autoimmunity of RA prior to visible joint symptoms. 
Smoking is a well-established exposure that associates with elevated risk of 
ACPA positive RA but not ACPA negative RA. It has been shown that smoking 
cause citrullination in the lung and has an association with the occurrence of anti-
citrulline immunity in RA (86-88). Alcohol consumption has been shown to have 
a significant inverse association with risk of RA (89-93). A higher body mass 
index is associated with increased risk of ACPA negative RA (93-95). It is not 
known yet if RA risk factors have an association with specific anti-citrullinated 
anti bodies and thereby can be potentially engaged in RA pathogenesis through 
inducing anti-citrulline immunity.
As it was mentioned, the effects of environmental risk factors differ between ACPA 
positive and ACPA negative RA patients (66). ACPA positive RA patients also show 
a more severe course of the disease compared to ACAP negative RA patients (96). 
Consequently, distinct phenotypic manifestations of RA have an association with 
distinct RA relevant risk profile. This implies ACPA positive and ACPA negative 
RA patients go through different pathogenic mechanisms to develop the disease. 
It is suggested that these antibodies, and the specific immunity they represent, are 
involved in the pathogenesis of RA. Since they are expressed many years before 
the onset of the disease, they have the prognostic ability. 
Increasing the knowledge in specific anti-citrulline immunity in association with 
established RA related environmental risk factors is vital to understand the role 
of environmental risk factors in etiology and pathogenesis of RA.
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2 AIM
2.1 OVERALL AIM
The aim of this thesis was to evaluate the role of new biomarkers in chronic 
inflammatory diseases focusing partly on atherosclerosis and its primary clinical 
manifestation MI, and RA. 
2.2 SPECIFIC AIMS
The specific aims of this thesis were:
• To investigate the association between sIL-6R and sgp130, respectively, with 
MI and explore the potential interaction between these biomarkers.
• To explore the association between sgp130 serum levels and c-IMT and c-IMT 
progression after 30 months follow-up in a European population with high-risk 
profile for CVDs.
• To identify genetic variants associated with sgp130 serum levels and to inves-
tigate if those genetic loci are associated with c-IMT as a marker of subclinical 
atherosclerosis.
• To identify if environmental risk factors of RA are associated with the presence 
of RA specific autoantibodies.
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3 MATERIALS AND METHODS
3.1 MATERIALS
3.1.1 SHEEP study
Study I was based on data from the Stockholm Heart Epidemiology Program 
(SHEEP), which is a large population-based case-control research designed to 
investigate genetic and environmental risk factors of relevance for the occurrence 
of MI. The study base was consisted of all Swedish citizens living in Stockholm 
county from 1992-1994, aged 45 to 70 without previous clinically diagnosed MI. 
3.1.1.1 Case identification and control selection 
Overall, 5452 participants were enrolled in the study, 2246 cases and 3206 controls. 
The cases were included in the SHEEP at the time of disease incidence at ten emer-
gency hospitals within the Stockholm county. Cases were diagnosed according to 
the diagnosis criteria for MI, accepted by the Swedish Association of Cardiologists 
in 1991-1994. In this thesis, only non-fatal cases (n=1213) were included that are 
patients who survived at least 28 days post-MI and had no  further MI before sample 
collection. Fatal cases (n=603) were excluded due to the absence of blood sampling.
Controls (n=1561) who matched on sex, age (five years interval) and hospital catch-
ment area were randomly selected from the study base within two days from case 
incidence. In order to substitute potentially nonresponsive controls, five controls 
per case were selected simultaneously. Occasionally both the first and potential 
substitute controls were contacted and included in the study due to the late response 
of the initial control. Therefore, there are more controls than cases in the study.
Both cases and controls candidates were identified through the National Patient 
Registry and were investigated if they had previous MI (ICD9-codes 410 or ICD-
10 I21).
Clinical investigations were undertaken on average three months after the index 
events, including blood samplings under fasting conditions with the collection of 
whole blood for DNA extraction, serum and plasma (EDTA and citrated). The serum 
samples were kept at -70°C until analyzed. To collect data on a large set of potential 
risk factors, cases and controls completed a questionnaire, which was complemented 
with a telephone interview, to complete missing information. Controls underwent a 
health examination as close as possible in time to the corresponding cases to avoid 
biases due to seasonal change in blood parameters. Non-fatal cases and controls 
had participation rate of 87% (n=1643) and 73% (n=2339) respectively. 
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Anthropometric measurements such as BMI (Kg/m2), systolic and diastolic blood 
pressures were evaluated. Other biochemicals were also measured such as insulin, 
total cholesterol, triglycerides, HDL cholesterol, CRP, serum glucose, blood lipids 
and TNF-α. 
3.1.1.2 Biomarker measurement
sIL-6R
The serum level of sIL-6R was assessed in 1785 serum samples from 682 cases 
and 1103 controls using MesoScale Discovery (MSD) Human Cytokine assay 
(Gaithersburg, MD, USA), following the manufacturer’s assay protocol. Samples 
were diluted 1:75, and the calculated concentrations from the standard curve were 
expressed in (ng/mL). The minimum detectable value for sIL-6R was 0.1 pg/mL. 
The intra-assay variability was asessed by running n=267 samples in duplicate 
within the same experiments, whereas the inter-assay variability was assessed by 
duplicating n=67 samples in separate experiments. The intra-and inter-assay coef-
ficient variations were 6.1 % and 3.8% respectively. According to the manufacturer, 
the recommended threshold is 15% and 18% for mean intra-assay and mean inter-
assay coefficient of variation, respectively. 
sgp130
The serum level of sgp130 were measured using an assay from R&D systems®, 
Quantikine® ELISA according to the protocol instructions. Because of lack and or 
inadequacy of serum, in total, 1726 serum samples were evaluated for sgp130, 664 
cases and 1062 controls. Samples were diluted 100 times, and serum concentrations 
(ng/mL) were derived from the standard curve. The intra variability (1.8%) and 
inter variability (12.1%) were calculated respectively by duplicating n=25 samples 
within a plate and n=37 samples in independent experiments. No specific threshold 
for intra- and inter-assay variability were suggested by the manufacturer for sgp130, 
although previous studies have reported an intra-assay variability <10–11% and 
inter-assay variability <10–16% (97, 98).
3.1.1.3 Ethical consideration
The SHEEP study was conducted in accordance with the Helsinki Declaration 
and was approved in 1991 by the Regional Ethical Review Board at Karolinska 
Institutet. Participants gave their oral informed consent since no written informed 
consent was in use.
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3.1.2 IMPROVE study
IMPROVE (carotid Intima-Media Thickness and c-IMT PRogression and the risk 
of Vascular Events) is a multicenter prospective study designed to investigate the 
association of c-IMT and c-IMT progression with the risk of future CVEs. From 
March 2004 to April 2005, 3711 subjects (men, N= 1772 and women, N=1931) 
aged from 55 to 79 years free of any CVDs but with medical history for at least 
three conventional CV risk factors (e.g. hypertension, diabetes, dyslipidemia, 
smoking and family history of CVDs) were selected by seven recruiting centers 
from five European countries: France (n=501 from Paris), Sweden (n=533 from 
Stockholm), Finland (n=1050 from two centers in Kuopio), Italy (n=1095 from 
Milan and Perugia) and the Netherlands (n=532 from Groningen). 
At baseline, every study participant completed an extensive questionnaire on lifestyle 
habits, former disease and treatment. Anthropometric measures were recorded, and 
a large biobank with whole blood, serum and plasma was established and stored at 
–80°C until used. For evaluating c-IMT changes overtime, subjects were  followed 
for three years, and ultrasonographic measurements were repeated at two time-points, 
at 15 months and 30 months, using the same ultrasonographic protocol applied at 
baseline. Smoking was defined as current smoking. Hypertension was defined if self-
reported and or diastolic blood pressure ≥90 mmHg and or systolic blood pressure 
≥140 mmHg and or treatment with antihypertensive drugs; Diabetes was defined as 
self-reported and or blood glucose level ≥7 mmol/L and or treat ment with insulin 
or oral hypoglycemic drugs. Hypercholesterolemia was defined as LDL cholesterol 
≥4.13 mmol/L and or treatment with cholesterol-lowering drugs. More details about 
study design have been described elsewhere (99).
3.1.2.1 Ultrasonographic measures
Participants underwent c-IMT measurements by trained sonographers using a 
Technos system (Esaote, Genova, Italy), equipped with a 5-10 Mhz linear array 
probe. Ultrasounds data were collected from the far walls of the left and right 
common carotid (CC), the bifurcation (Bif), the internal carotid artery (ICA) 
and the 1st centimeter of common carotid (I_CC) in anterior, lateral, and pos-
terior angles. All measurements were done in at least three different frames at 
three time-points: at baseline, after 15 months and after 30 months of follow-up. 
The baseline c-IMT ultrasonographic measurements selected for the study II were: 
1) IMTmean: the average of mean c-IMT for all the eight segments (left and right I_CC, 
CC, Bif and ICA); 2) IMTmax: the largest c-IMT value recorded among all eight the 
segments investigated; 3) IMTmean-max: the average of the eight max c-IMT values 
recorded at each of the eight segments. c-IMT baseline values are reported in mm. 
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c-IMT was also measured after 15 and 30 months of follow-up and the progression 
of c-IMT was calculated at 15 months, by dividing the difference between the 15 
months and corresponding baseline value by the length of intervening time period. 
c-IMT progression at 30 months calculated by linear regression model between 
three-point measurements and expressed in mm/year.
3.1.2.2 Measurement of serum sgp130 levels
Serum sgp130 levels were measured by DuoSet ELISA development kits of human 
sgp130 (DY228) provided by R&D Systems ® (R&D systems Minneapolis, MN, 
USA). Samples required a 100-fold dilution and the range of a standard curve was 
20 ng/mL to 0.25 ng/mL. Briefly, 96-well plates were coated by diluted capture 
antibody in the working concentration of 4.0 μg/mL sealed and incubated overnight 
at room temperature. Then for blocking step, 2% Bovamin serum albumin was 
used (200 μL/well) and incubated for one hour at room temperature. Detection 
antibody in working concentration of 0.08 μg/mL was added and incubated for 
2 hours at room temperature. To optimize the protocol for serum samples, differ-
ent concentrations for capture antibody and detection antibody were tested. To 
validate the sample diluent (0.2% BSA in 1X PBS), linearity test was performed 
by adding (spiking) known amount of human recombinant sgp130 to the samples. 
Microplate reader set to 450 nm and a correction wavelength of 540 nm or 570 nm.
To calculate the intra- and inter-assay coefficient variation, a known concentration 
of 5 ng/uL from recombinant sgp130 was duplicated in both the same and two 
different plates. The intra- and inter-assay coefficients of variation were 1.88% 
and 12.1% respectively.
3.1.2.3 Genotyping; CardioMetaboChip 200k and the ImmunoChip
Genomic DNA from IMPROVE study participants was genotyped using two 
custom-made genotyping arrays; 1) CardioMetaboChip 200k: a custom Illumina 
iSelect genotyping array for the study of genetic variants associated with meta-
bolic and CVDs, and 2) ImmunoChip: is a custom Illumina Infinium HD array 
containing approximately 200,000 variants mapping in genetic regions identified 
by GWAS as potentially relevant for immune-mediated diseases. More detailed 
information on these two arrays can be found (100, 101).
3.1.2.4 Ethical consideration 
The IMPROVE study was funded by the Vth European Union program. The 
study was carried out in accordance with the Helsinki Declaration and approved 
by the IRB at each one of the seven recruiting centers: 1) the Regional Ethics 
Review Board at Karolinska Institutet, Stockholm Sweden, 2) IRB at the Groupe 
Hôpitalier Pitie-Salpetriere, Paris, France, 3) the IRB Comitato Etico delle Aziende 
Sanitarie della regione Umbria, Perugia and 4) the IRB at the Ospedale Niguarda 
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Ca´Granda, Milano, both in Italy, 5) the IRB at the University Hospital Groningen, 
Groningen, the Netherlands, 6) the IRB Hospital District of Northern Savo and 7) 
and the IRB at University of Eastern Finland, both in Kuopio, Finland. Each par-
ticipant provided two different written consents one for general participation in the 
study and one for genotyping. 
3.1.3 EIRA study
The EIRA (Epidemiological Investigation of Rheumatoid Arthritis) is an ongoing 
population-based case-control study since 1996 recruited subjects 18-79 years aged 
from defined (southern/central) regions of Sweden. Only cases, who were selected 
from May 1996 until November 2009, were included for the analysis in this study. 
The participation rate for the cases was 94%.
3.1.3.1 Case identification and control selection 
Cases (n=2859) were defined as RA patients diagnosed according to the 1987 ACR 
criteria by rheumatologists within twelve months after the onset of joint disease symp-
toms. Sampling was done at the first visit before applying any RA specific medication.
Controls (n=581) were randomly selected through the Swedish national register and 
matched for age, sex and residential area, more details on study population can be 
found in (102). Data derived from the questionnaire on lifestyle-related risk factors 
and blood samples of all participants were collected at baseline for further genetic 
and serological analysis. 
Subjects were defined regarding exposure to smoking to two categories: “smokers” 
and “never-smokers”. Smokers are individuals that presently smoke, had smoked 
before, or those who occasionally smoke whereas never-smokers had not ever smoked 
cigarettes. Similarly, regarding alcohol intake, participants were classified either as 
”ever-drinker” or ”never-drinker”. Moreover, the label ”high alcohol consumer” 
was assigned to men consuming at least 168 grams of alcohol per week, and to 
women having at least 108 grams per week. All others were classified as low alco-
hol consumers. BMI was classified as obese (≥30 kg/m2) or not obese (<30 kg/m2). 
For additional analysis, two other categories were defined: 1) overweight or obese 
(≥25 kg/m2) and 2) normal or underweight (<25 kg/m2). 
3.1.3.2 Measurement of serum level of IgG specific ACPA
A microarray-based on the ImmunoCAP ISAC system (Phadia AB, Uppsala, Sweden) 
was customized to measure the level of antibodies against various citrullinated pep-
tides. This array has been validated using ELISA-based technology. Details were 
described in (76). More than 40 different citrullinated peptides and their arginine-
containing counterpart were immobilized in a microarray, and the reactivity towards 
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these peptides was measured based on detected fluorescence intensities. Reactivity 
towards 19 citrullinated peptides was included in study III (Table 3). 
The cut-offs for the presence of antibody against each citrullinated peptide was 
calculated based on the 98th percentile in the 581 healthy controls. It is assumed, 
2% of the general population would give reactivity toward any citrullinated peptide 
regardless of having RA, which can be because of assay noise or unspecific binding.
3.1.3.3 Measurement of serum level of RF isotypes
In EIRA serum level of IgM, IgG and IgA-RF were measured in RA patients using 
EliA immunoassay on Phadia 2500 (Phadia GmbH, Freiburg, Germany).
3.1.3.4 Ethical consideration
Participants were informed about the study by health care professionals at the rheu-
matology clinics, provided oral consent which was documented in their medical 
records. Ethical approval was obtained from the Regional Ethical Review Board 
at Karolinska Institutet, Stockholm, Sweden.
3.1.4 eRA-Umeå study
The early RA (eRA-Umeå) cohort consists of 1022 patients (692 women and 330 
men) fulfilling the 1987 ACR criteria for RA diagnosed at the Departments of 
Rheumatology in the four most northern counties of Sweden, who were included 
in the National Register for early RA. All subjects were recruited to eRA-Umeå 
cohort between Jan 1996-April 2012. Data on lifestyle and environmental risk 
 factors for RA were collected through a self-reported questionnaire. Plasma samples 
were collected at baseline and kept in -80°C freezers until use (103). Twenty-two 
patients lacked information regarding smoking. 
3.1.4.1 Measurement of plasma level of IgG specific ACPA 
Expression of IgG specific antibodies against citrullinated peptides were assessed in 
plasma of 1011 cases using the custom-made array chip (Thermo Fisher Scientific, 
ImmunoDiagnostics, Uppsala, Sweden). Citrullinated peptide antigens were as fol-
low: α-enolase peptide (CEP-1), Collagen type II (C1, F4-R-cit, F4-cit-cit and F4-cit-R), 
fibrinogen (Fibα36-50, Fibα563-583, Fibα580-600, Fibα621-635, Fibβ36-52, Fibβ60-74), Filaggrin 
(CCP-1), vimentin (cit-Vim2-17, cit-Vim60-75) and hnRNP-A3 (Pept-Bla-26, Pept-1, 
Pept-5, PeptZ1and PeptZ2). The cut-off value for positivity was set at the 98th 
percentile of 477 healthy controls for all the antibodies (103). 
3.1.4.2 Ethical consideration
The patients gave their written informed consent, and the Regional Ethics Committee 
at Umeå University Hospital approved the study.
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3.2 STATISTICAL ANALYSIS
3.2.1 Study I
Differences between cases and controls were calculated by Kruskal–Wallis test for 
continuous variables and by chi-square (χ2-test) for the binary variables. 
Levels of sIL-6R and sgp130 were categorized in quartiles according to the 
serum levels in the controls. sIL-6R quartile boundaries were (ng/mL) Q1≤31.6, 
31.6<Q2≤40.8, 40.8<Q3≤54.5, 54.5<Q4, and sgp130 quartile boundaries were 
(ng/mL) Q1≤308.8, 308.8<Q2≤365.6, 365.6<Q3≤432.6 and 432.6<Q4. 
Logistic regression models were applied to compute the odds ratio for MI in asso-
ciation with the high level of sIL-6R and sgp130, respectively. Exposure to high 
sIL-6R and sgp130 was defined according to the cut-off values of the 75th and 
90th percentiles of the distribution of these  biomarkers in controls. The associa-
tion results reported as OR with 95% CI were calculated for the exposure to high 
levels of sIL-6R and sgp130, respectively, considering ≤75th and ≤90th percentiles 
as reference categories.
In the crude model (model 1), analysis was adjusted for sex, age and hospital 
catchment area. Based on previous literature additional potential confounders were 
included in model 2; hypertension (individuals on antihypertensive drug therapy 
or with blood pressure ≥140/90 mmHg), diabetes (subjects with a glucose value 
>6.7 mmol/l and or treatment with insulin and or other drug treatment), hyper-
cholesterolemia (total cholesterol ≥6.4 mmol/l or receiving any lipid-lowering 
medication), current smoking and BMI. 
To investigate if circulating sgp130 levels can change the association between 
sIL-6R and MI, first the association between high sIL-6R (>75th) and risk of 
MI was stratified based on the median value (365.6 ng/mL) for sgp130 using 
logistic regression. Results were expressed as OR with 95% CI. Due to the low 
number of study participants in the group having sIL-6R>75th and sgp130>90th, 
the median was used as the cut-off for the sgp130. However, resembling analysis 
was performed using the 90th percentile cut-off for the sgp130 distribution, and 
similar results were achieved. A model, including adjustments for the previously 
mentioned confounders was also applied. 
When there is a biological interaction, the effect of the presence of two interact-
ing factors together is higher than the additive effect of each one of them (104). 
Therefore, the interaction between serum levels of sIL-6R (low≤75th /high>75th) 
and sgp130 (low≤50th /high>50th) was modelled by defining four exposure groups:
1) the group exposed to sIL-6R>75th but sgp130>50th
2) the group exposed to sIL-6R>75th but sgp130≤50th
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3) the group exposed to sIL-6R≤75th but sgp130≤50th
4) the group exposed to sIL-6R≤75th but sgp130>50th (this group had the lowest 
risk and was used as the reference group)
The relative risk of MI was computed for every exposure group and was compared 
with the reference group. Analysis were adjusted for sex, age, hospital catchment 
area, hypertension, diabetes, hypercholesterolemia, BMI and smoking.
Afterwards, the potential synergistic interaction between the two biomarkers was 
explored by calculating the attributable proportion (AP) and the synergy index (S) 
together with 95% CI. The AP>0 indicates the presence of an interaction. The S 
≥1.0 indicates a positive interaction and synergistic effect, while S <1.0 represents 
a negative interaction and antagonistic effect. For the AP and the S, respectively, 
95% confidence intervals were calculated.
All statistical analyses were performed using StataCrop LP (College Station, TX) 
version 13. The interaction analysis was calculated using the Epinet sheet.
3.2.2 Study II
Due to skewed distribution of sgp130 serum levels, the log-transformed values 
were used for the genetic association analysis. The quality control for genetic data 
has been carried out on both the individual genotyping chip and the combined 
dataset. More information on number of the subjects and including and excluding 
criteria in study II is illustrated in Figure 3.
After quality control procedure 360,842 SNPs contained in the combined 
CardioMetabo-Immuno chip from 3439 participants were assessed for asso-
ciation with serum sgp130 levels, by means of multivariable linear regression 
analysis under the assumption of an additive model of inheritance. Results were 
reported as beta (β) and standard error (SE) and p-value after adjustment for age, 
sex and population structure (using multidimentional scaling (MDS) components). 
p-value≤1×10−5 was set as the significance threshold and p-values>1×10−5 but ≤ 
1×10−4 as the suggestive association threshold. 
Data from a public source of tissue-specific gene expression and regulation was 
used to report the effect of SNP genotype on tissue expression (105). 
The association between potentially relevant SNPs to sgp130 serum level and 
c-IMT baseline measures were analyzed using linear regression. The first model 
was adjusted for the potential confounding factors age, sex and latitude while the 
second model was also adjusted by sgp130.
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General epidemiological analyses were calculated by using SAS version 9.4 (SAS 
Institute, Cary, NC) and SNPs association analysis was done using PLINK v1.07.
In the preliminary analysis performed on the IMPROVE, sgp130 serum levels 
differed significantly between men and women; therefore, the analyses stratified 
by gender. Since sgp130 serum levels (ng/mL) were not normally distributed, the 
measurements were categorized in quartiles based upon the distribution in the 
entire IMPROVE studies. Quartiles boundaries are Q1≤ 452.2, 452.2 <Q2≤ 566.6, 
566.6< Q3 ≤705.5 and 705.5≤ Q4. Differences among quartiles were calculated 
by Kruskal-Wallis.
Figure 3. Flowchart summarizing the IMPROVE study participants included in study II.
IMPROVE study participants 
(n=3711) 
Missing sgp130 (n=67) 
IMPROVE study participants with available c-
IMT measurements  
(n=3703) 
Failing quality control (n=86) 
IMPROVE study participants with available 
sgp130 measurements (n=3636) 
Missing genotype 
(n=111) 
IMPROVE study individuals with available genotype and 
sgp130 measurements  
(n= 3439) 
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Multiple linear regression models were applied to investigate the association 
between level of sgp130 and c-IMT at baseline and after 30 months follow-up 
in two models. The first regression model was adjusted for sex, age and latitude, 
while the second model also included traditional CV risk factors as covariates 
(hypertension, hypercholesterolemia, diabetes, BMI and smoking).
p-value ≤ 0.05 was set as significant in all analysis. All statistical analyses were 
performed using StataCrop LP (College Station, TX) version 13.
3.2.3 Study III 
To investigate the correlation between all pairs of antibodies in EIRA and eRA-
Umeå, the Pearson correlation coefficient was calculated, which is a measure of 
the strength of the linear relationship between every two antibodies and varies 
from +1 to -1. 
The χ2-test was used to compare the frequency of presence of each antibody in 
the two studied cohorts.
Initially, univariate logistic regression was used to model the probability of the 
presence of 22 RA specific antibodies in terms of being exposed to RA environ-
mental risk factors (smoking, alcohol consumption and BMI), fitting a separate 
model for each antibody. To tackle the mediation and colliding effect of antibodies 
to the presence of each other, all antibodies were modelled jointly in the logis-
tic regression analysis. The analysis was performed separately for smoking and 
alcohol and BMI in EIRA. Results were presented as OR and p-value and false 
discovery rate (FDR). 
p-value less than 0.05 was taken as nominally significant. FDR was calculated by 
p.adjust function to correct for multiple testing and FDR ≤ 10% was considered 
as acceptable. To assess if the indicated significant associations are mediated by 
the presence of other antibodies, potential colliders were removed, and associa-
tion was reanalyzed. 
The RF isotype data in the eRA-Umeå cohort was not available, therefore the logistic 
regression model was performed for 19 antibodies and smoking. Data on alcohol 
consumption and BMI in eRA-Umeå were not available. Furthermore, this set of 
analysis was repeated in the merged EIRA and eRA-Umeå participants (n=3797).
Homogeneity between the two cohorts was tested using a likelihood ratio test to 
assess if the results differed significantly among the cohorts. All statistical analysis 
was performed in the R software v. 3.3.3 for Windows.
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4 RESULTS AND DISCUSSION
4.1 STUDY I, II 
4.1.1 Association of sIL-6R and sgp130 with the risk of MI
Results from study I showed that median levels of sIL-6R were higher in cases 
with MI than controls at inclusion in SHEEP. In line with our results, other studies 
have indicated increased levels of sIL-6R in MI cases (45) and patients with CHD 
(44). It has been shown that sIL-6R mediates the pro-atherogenic effect of IL-6 in 
endothelial cells via trans-signaling by stimulating the production of chemokine and 
increasing the expression of adhesion molecules (42, 106). Furthermore, elevated 
sIL-6R has been reported in association with endothelial dysfunction and arterial 
stiffness (107). Previous studies did, however, measure sIL-6R at the event, which 
likely mirroring the acute inflammatory phase. In SHEEP sIL-6R was measured 
three months after MI which likely reflect extended chronic inflammation.
Our data suggest that increased sIL-6R levels (>75th) are associated with an increased 
risk of MI (OR=1.6, 95% CI 1.3-2.0), even though adjusting for potential con-
founders reduced the risk (OR=1.4, 95% CI 1.1-1.8). Different cut-off limits (75th 
and 90th percentile) were tested for sIL-6R and sgp130, based on distributions in 
controls. Using the 90th percentile as a threshold for sIL-6R as expected resulted 
in an even higher risk estimation (OR= 1.7, 95% CI 1.2-2.3). Results from con-
ditional logistic regression models also gave comparable ORs in crude (OR= 1.5, 
95% CI 1.2-1.9) and adjusted (OR= 1.4, 95% CI 1.0-1.8) models.
A lab in Germany highlighted a buffer system for IL-6 trans-signaling formed 
by sIL-6R and sgp130 (37). Based on this argument, sgp130 inhibits the trans-
signaling through binding to the IL-6/sIL-6R complex with a high affinity (10 pM) 
after the complex was unified, this is 100 times higher than the affinity of bind-
ing sIL-6R to IL-6 (1nM) (34). Therefore, the presence of high levels of sgp130 
prevents IL-6/sIL-6R to bind membrane-bound gp130 and thereby also prevents 
the activation of IL-6 trans-signaling. 
According to the manufacturer, it is not distinguishable if unattached sIL-6R or 
sIL-6R in complex with IL-6 was measured. It could be theorized that the measured 
sIL-6R in the SHEEP cohort partly reflects the complex of sIL-6R/IL-6 leading 
trans-signaling pathway. Alternative interpretation can be the higher unattached 
sIL-6R in the patients is joined to IL-6 and initiating the trans-signaling. 
No difference in the serum level of sgp130 was observed between cases with MI 
and controls in the SHEEP. In agreement with our results, other studies reported 
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no difference between sgp130 serum level in cases with MI, CHD and controls 
(45). In a study of IL-6 signaling in patients with MI, no correlation was observed 
between sgp130 and intensity of myocardial necrosis (108). However, higher 
sgp130 serum concentrations were reported as a marker of inflammation in other 
diseases, e.g. RA, inflammatory bowel disease (109) and colon cancer (110).
In the SHEEP no association was found between sgp130 and MI using the 50th 
and 75th percentile as a cut-off, while exposure to very high serum sgp130 (>90th 
percentile) was inversely associated with risk of MI when adjusting for potential 
confounders (OR=0.68, 95% CI 0.5-0.9). When adding covariates one by one to 
the model, diabetes decreased the ORs to a notable extent, suggesting the actual 
effect of diabetes as a confounder on this association. In line with this result, Italian 
data from older individuals (age ≥ 65 years) demonstrated an association between 
metabolic syndrome and high plasma levels of sgp130 (111). Moreover, in another 
study from Poland, an independent negative association between sgp130 and 
insulin resistance has been indicated in women with polycystic ovarian syndrome 
proposing an inhibitor role for sgp130 in IL-6 trans-signaling in insulin-resistant 
conditions (112). 
An elevated level of sgp130 has been shown to block the IL-6 trans-signaling via 
IL-6/sIL-6R complex (113) and have a protective effect on the inflammatory dis-
ease progression (114). High sgp130 can dismiss retaining of chronic inflammation 
in systemic diseases like atherosclerosis by inhibition of the IL-6 trans-signaling 
via binding to IL-6/sIL-6R complex. Administration of recombinant sgp130 in the 
mouse model of atherosclerosis has indicated an inhibition of the rapid increase in 
the number of smooth muscle cells and decline in atherosclerotic plaque progres-
sion (50, 115, 116). This explains the reduction of the MI risk in the presence of 
high sgp130 serum level. Previous studies have indicated that only extreme levels 
of biomarkers might influence risk of disease (117, 118), which is in accordance 
with detecting an association only for the 90th percentile of sgp130 levels here.
Similar to sIL-6R, there was no possibility to recognize if measured levels of 
sgp130 in the SHEEP is unattached or attached to sIL-6R/IL-6 complex (sIL-6R/
sgp130/IL-6). Thus, one can speculate sgp130 in either form can inhibit the trans-
signaling pathway and deduce the susceptibility to MI.
4.1.2 Interaction analysis
Results from interaction analysis revealed an indication of a biological interac-
tion between high sIL-6R (>75th percentile) and low sgp130 (<50th percentile) 
(AP= 0.19, 95% CI -0.2 – 0.5 and S index= 1.7, 95% CI 0.5-6.1). It is worthy 
of note that a larger population would be needed to conclude on the presence of 
interaction between sgp130 and sIL-6R. Study of biological interaction between 
27
two biomarkers can provide an approach to understand the biological mechanism 
underlying development of CVD and specifically atherosclerosis.
As outlined earlier, binding of sgp130 and IL-6/sIL-6R complex can inhibit the 
progression of IL-6 trans-signaling pathway. Research performed on mice indi-
cated that the administration of sgp130 has significant protective effect on athero-
sclerosis. It showed that sgp130 reduced the atherosclerotic plaque development 
and progression through nullifying the IL-6/sIL-6R trans-signaling independently 
of classic-signaling (50). This suggests that sgp130 may antagonize the effect of 
IL-6/sIL-6R complex on the progression of atherosclerotic lesions. A recombinant 
form of sgp130 is in fact now tested as an anti-inflammatory drug in phase 1 clini-
cal trials (54). Nevertheless, the larger study material than SHEEP is required to 
achieve a proof on synergism or antagonism and provide more accurate estimates.
4.1.3 Genetic variants associated with serum sgp130 levels
In study II the association of genetic variants with the level of sgp130 was investigated 
in IMPROVE. Around 360,842 SNPs passed quality control and were analyzed for 
association with log-transferred sgp130. Although the commonly accepted p-value 
in GWA studies is ≤1×10−8, this study utilised more relaxed p-value thresholds for 
significance (≤1×10−5) as well as for suggestive association (≤ 1×10−4). This can in 
part be motivated by the fact that this was not a GWA study, but a more in-depth 
investigation of the loci which are part of the two genotyping arrays. Only two SNPs, 
rs10935473 mapping at chromosome (Chr) 3 and rs1929666 at Chr 10 surpassed 
chosen p-value threshold for significant association with sgp130. 24 SNPs surpassed 
the suggestive association threshold level. The manhattan and locus plot of the 
association p-values does not show very distinct peaks of associations around these 
SNPs, although a few of the neighbouring SNPs also show suggestive associations. 
The indicated SNPs on chromosome 3, rs10935473, have moderate correlation 
(r2:0.67) to rs9858592, placed in the ST3GAL6-antisense RNA 1 (ST3GAL6AS1). 
According to the genotype-tissue expression (GTEx) project reports, the effect allele 
at both SNPs have association with reducing the expression of ST3GAL6AS1 in 
different tissues like adipose tissue, the heart and the arterial wall as well as inverse 
association with circulating sgp130.
ST3GAL6AS1 have a role in the regulation of cell adhesion molecules. Molecular 
cell adhesion intervenes in extravasating the inflammatory cells from the circulation 
and accumulate on the vascular endothelium in the early stage of atherosclerosis. 
Besides, rs9858592 is in moderate correlation with rs865474, which is also located 
in ST3GAL6 and has a history of association with BMI. 
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Rs74760246 (β= -0.028, p-value= 1.21×10−5) and rs3087409 (β= 0.029, 
p-value=2.70×10−5) were the only two SNPs in this study that previously have 
shown association with risk of inflammatory diseases as well as CVDs. rs74760246 
located on Chr 1 has a powerful correlation (r2>0.8) with rs1421389 and rs10494757 
placed at DENNB1, which is a gene known for the association with the chronic 
inflammatory diseases (119, 120). rs3087409 mapping at WRN on Chr 8 corre-
lated with a SNP formerly associated with premature ageing as well as the risk 
for MI and stroke (121). 
The genetic loci that some of the identified suggestive SNPs mapped at, have 
been formerly associated with regulating glucose and cholesterol metabolism, e.g. 
rs300624 on Chr 1 that recognised as liver receptor homolog 1 (122), rs3813774 on 
Chr 19 and rs73063812 on Chr 7 have all suggestive inverse association with serum 
levels of sgp130. Furthermore, rs16932962 on Chr 9 in TTC39B and rs1681503 
on Chr 11 in ARAP1 have suggestive positive association with sgp130. TTC39B 
slightly correlated with mentioned suggestively associated SNPs has association 
with low HDL levels (122). 
In total, disregarding the chosen significance threshold, these results propose that 
SNPs involving in regulating sgp130 are also regulating cardiometabolic pheno-
types that have a minor inflammation phenomenon in common.
4.1.4 Association of sgp130 and c-IMT
Results from a preliminary analysis in IMPROVE showed women with higher 
sgp130 level had smaller c-IMT (markers of subclinical atherosclerosis) at baseline 
as well as the smaller progression of c-IMT after 30 months. Preliminary results 
from multiple linear regression indicated sgp130 has significant inverse relation-
ships with c-IMT at baseline in women, but no significant relationships to c-IMT 
change over time in either men or women. The opposite direction of the associa-
tion between c-IMT and sgp130 is in line with a therapeutic effect of sgp130 on 
atherosclerosis progression. Data from an animal study showed applying recom-
binant sgp130 led to regression of atherosclerotic plaques (50). 
It must however be noted that no firm evidence of the association between c-IMT 
and sgp130 was observed in IMPROVE, therefore, further research is required to 
confirm or reject the weak associations detected here. 
4.1.5 Association of the SNPs associated with sgp130 
with c-IMT 
SNPs that showed signs of association with circulating sgp130 levels were evalu-
ated for association with c-IMT at baseline in IMPROVE. rs17688225 on Chr 14 
was the only SNP inversely associated with c-IMT measures (c-IMTmean: β=−0.010 
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SE=0.005, p-value=0.0251; c-IMTmean–max: β=−0.010 SE= 0.005, p-value=0.0347; 
c-IMTmax: β=−0.025 SE=0.009, p-value=0.0049). Interestingly this SNP had a sug-
gestive positive association with circulating sgp130 (β=0.030, p-value=4.77×10-5), 
which goes in line with the atheroprotective effect of sgp130 (123). 
4.2 STUDY III
4.2.1 Correlation between ACPAs
The pairwise correlation between the presence of RA-specific antibodies against 
specific peptides or isotypes of RF were visualised in the two heatmaps plots 
(Figure 4). A similar pattern of correlation between different anti-citrullinated 
peptide antibodies was observed in the EIRA and eRA-Umeå cohorts. These 
biomarkers were positively correlated in different degrees, and they were not 
clusters by the protein of origin. One group of antibodies including antibodies 
against CEP-1, Cit-Pept-5, Cit-Pept-Z1, Cit-Pept-Z2, CCP-1, Cit-PeptBla26, 
Cit-Fibβ36-52, Cit-Fibα621-635 and Cit-Fibα563-583 showed a very strong correlation to 
each other. Of note, these belong to the different source of citrullinated peptides: 
α-enolase, hnRNP A3, filaggrin and fibrinogen. Another set of antibodies includ-
ing Cit-Fibα36-50, Cit-C1, Cit-F4Cit-R, Cit-Pept-1were less correlated to each other 
and the other reactivities against citrullinated peptides.
IgA-, IgG- and IgM-RF in EIRA demonstrated a strong positive correlation to 
each other but a rare co-occurrence with a highly correlated group of ACPAs. RF 
is less specific for RA compare to ACPAs and is also used as a serological marker 
for other autoimmune diseases. Thereby, two distinct molecular mechanisms for 
the production of RF and ACPAs are presumable (124).
The correlation between different reactivities can be due to cross-reactivity, 
epitope-spreading, shared causes, or isotype switching in terms of RF. Cross-
reactivity is one of the reasons that can explain the co-occurrence of reactivity 
towards different citrullinated peptides. The existence of similar epitopes on two 
or more citrullinated peptides can eventuate binding of the antibody specific to 
one of these peptides to the other one. 
It has been recognized during recent years that ACPA can also cross-react to 
another post-translationally modified motifs, which indicated that cross-reactivity 
is wide-spread (125, 126). The co-occurrence of antibodies reported in this study is 
in line with epitope spreading, the process where the antigens that are recognized 
increases or shifts during an immune response. Epitope spreading happens years 
before RA onset (84, 127). Jointly this indicated that the presence of reactivity 
towards one antigen often mediates the presence of reactivity against other anti-
gens. Using epidemiological terms, this means that different reactivities mediate 
the presence of each other. 
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4.2.2 Association between smoking and presence of ACPAs
For association analysis initially, a separate model for each antibody were fitted. 
Almost all antibodies in EIRA demonstrated a significant positive association with 
smoking except for anti-Cit-C1and anti-Cit-F4Cit-R (128). These results were in 
accordance with causal paths between smoking and antibody presence, and with 
extensive mediation due to cross-reactivity and or epitope spreading. 
In this study, the interest was to assess whether environmental risk factors of RA 
cause RA by influencing the presence of specific antibodies. These antibodies are 
correlated to each other with different strength, but the knowledge about biological 
mechanisms of these relationships are limited. Thus, to avoid detecting associa-
tions driven by mediation, a logistic regression model was used, which evaluated 
all antibody jointly. That revealed in EIRA, being an ever smoker had a negative 
association with having antibodies towards Cit-Vim60-75 and Cit-C1 as well as a 
positive association with having IgA-RF, anti-CEP-1 and anti-Cit-Pept-Bla26 anti-
bodies (p-value ≤ 0.05). 
Considering the FDR, only IgA-RF (OR=2.14, FDR=1.6*10-8 %) and anti-Cit-
Vim60-75 (OR=0.69, FDR=3.2%) remained significantly associated with smoking 
in EIRA. In eRA-Umeå, only anti-Cit-Fib36-50 antibody was significantly associ-
ated with smoking after considering the multiple testing (OR=1.78, FDR=0.070).
Results from merged analysis, including both EIRA and eRA-Umeå cases, indicated 
smoking had a negative association with anti-Cit-C1(OR=0.71, FDR=3.8%) and anti-
Cit-Vim60-75 (OR=0.77, FDR=8.2%) antibodies as well as a positive association with 
anti-Cit-Fibα36-50 (OR=1.32, FDR=3.8%) and anti-CEP-1 (OR=1.39, FDR=1.6%). 
The merged analysis thereby strengthened the confidence of association between 
antibodies toward CEP-1 and Cit-C1 and smoking but downplayed the association 
between anti-Cit-Vim60-75 antibody and smoking, which was not observed in eRA-
Umeå at all. This emphasized a requirement of more investigation to conclude on 
the true effect of anti-Cit-Vim60-75 antibody and smoking. 
Several studies have investigated the association between smoking and RA (129). 
It is been hypothesized that smoking contributes to RA development by inducing 
protein citrullination in the lung and thereby causes chronic inflammation and ini-
tiation of anti-citrullinated peptide immunity in the lungs of the individuals (130). 
The low level of ACPA has been detected in both non-RA inflammatory diseases 
affected the lung tissues and in bronchoalveolar lavage of non-smoker RA patients 
(131, 132). Lungs, as the second most affected organs by RA, can be the anti-
citrullination immunity onset point (130). 
The presence of mediator and collider may affect the association between environ-
mental risk factors and the presence of RA specific ACPA (Figure 5).
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According to the immunological literature, antibodies can mediate the presence 
of each other, which from the epidemiological point of view can be translated to 
giving both mediator and collider role to antibodies in the production process of 
each other (Figure 5) (104, 133). A Mediator is a variable that intervenes the direct 
relationship between exposure and outcome, whereas a collider is a  variable that 
is causally influenced by exposure and outcome. As mentioned earlier, including 
colliders in the regression model can lead to biased results and false associations. 
Therefore, to understand the role of environmental risk factor in the patho genesis 
of RA through immunity towards specific citrullinated peptide, in EIRA and 
merged data, potential colliders were excluded, and the association analysis was 
reassessed for remaining antibodies. 
In this regard, to investigate if the association between IgA-RF and smoking in 
EIRA is a direct association, we excluded potential colliders (other four smoking-
associated antibodies: Anti-Cit-Vim60-75, anti-Cit-C1, anti-CEP-1 and anti-Cit-Pept-
Bla26) thereafter analyzed the logistic model for 18 antibodies. The results from 
EIRA showed a significant positive association between IgA-RF and smoking; 
this association was robust when excluding potential colliders. 
Association between smoking and IgA-RF was far stronger than the positive 
association of anti-CEP-1 IgG and anti-Cit-Pept-Bla26 IgG with smoking. Several 
studies have shown smoking has a strong association with RF compare to ACPA 
(131, 134-136). It was shown in this study, the correlation of IgA-RF with reactivity 
towards citrullinated peptides was not strong (r2= 0.13-0.43). This was in agree-
ment with an earlier study performed in EIRA, indicating a difference between 
IgA- and IgG- class antibodies to CCP2 cyclic citrullinated peptides in association 
with smoking. In that study they found an association between  smoking and IgA 
CCP2 but not between smoking and IgG CCP2 (137). This suggests that  smoking 
can lead to citrullinating of autoantigens such as fibrinogen and α-enolase and 
vimentin in the lungs and cause inflammation in the lung’s mucosal surfaces, 
Figure 5. Collider (Left panel) and mediator (Right panel) scenarios in association with 
exposure and outcome. Examples are hypothetical.
Exposure Outcome 
Collider 
 Smoking  e.g. Presence of anti-Cit-Vim60-75
e.g. Presence of IgA-RF
Exposure Outcome 
Mediator 
Smoking  e.g. Presence of Cit-C1
? ? 
e.g. Presence of Cit-Vim60-75
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which leads to IgA ACPA responses towards the citrullinated peptides (131, 134). 
Increased IgA ACPA has been reported before in early RA patients, and it is known 
that IgA is the primary antibody of the mucosal immune system (138, 139). As a 
future perspective of ACPA studies, it will be of interest to assess the relationship 
between smoking and IgA response to ACPA. 
The potential colliding effect of IgA-RF on the association between smoking 
and anti-Cit-Vim60-75 antibody in EIRA also was avoided by excluding IgA-RF, 
anti-Cit-C1, anti-CEP-1 and anti-Cit-PeptBla26 antibodies from the model. The 
results confirmed a negative association between anti-Cit-Vim60-75 and smoking 
among RA patients in EIRA. A similar analysis was done in the merged dataset to 
avoid the colliding effect. Every time three of anti-Cit-Vim60-75, anti-Cit-Fibα36-50, 
CEP-1, anti-Cit-C1 were excluded from the regression model and evaluated the 
effect of the association on the left one. After all, in the merged data, smoking 
showed a direct and independent association with anti-Cit-Fibα36-50, anti-CEP-1 
and anti-Cit-C1 antibodies but not with anti-Cit-Vim60-75. 
The negative association between anti-Cit-Vim60-75 and smoking was not robust 
in our different analyses. Overall, it was unexpected to find a negative associa-
tion between a citrullinated antigen and smoking. Therefore, another statistical 
approach was taken to avoid mediation effects in the found negative association. 
A stratified subset of the population that did not express any of the antibodies 
positively associated to smoking was therefore utilized to assess the association 
between smoking and anti-Cit-Vim60-75 in a univariable model. By this approach, 
the negative association between smoking and anti-Cit-Vim60-75 was corroborated 
in EIRA (OR=0.60, p-value=6.7*10–3), but not in the merged dataset. The result 
from sensitivity analysis on the merged data was in line with the result of associa-
tion analysis for anti-Cit-Vim60-75 and smoking after removing the colliders effect.
The stratified analysis was also repeated to assess the real negative association 
between Cit-C1 and smoking in the merged dataset. No negative association 
remained (OR=0.72, p-value=0.11) after excluding antibodies towards anti-Cit-
Vim60-75, anti-Cit-Fibα36-50 and CEP-1. 
Results from previous studies and our own using univariate regression showed 
a weak positive association between smoking and anti-Cit-Vim60-75 antibody. It 
is likely that due to the positive correlation between anti-Cit-Vim60-75 antibody 
and other positively associated antibodies with smoking, the negative association 
has been covered up in the univariate regression model. Although in the merged 
analysis, the significant negative association between smoking and anti-Cit-Vim60-75 
was disappeared after removing collider effects. Hence further investigation is 
required to deduce the presence of a negative association between smoking and 
anti-Cit-Vim60-75 antibody. 
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In EIRA, we had available data on irregular smokers who might have differ-
ent pathophysiology of RA from regular smokers. The association analysis was 
repeated on individuals excluded irregular smokers, and the results did not alter.
The homogeneity of association signals between the two cohorts, EIRA and eRA-
Umeå, was evaluated using a likelihood ratio test; results did not differ significantly 
among the cohorts (p-value=0.062). 
In summary, our study indicated that smoking might give rise to antibodies against 
a few antigens, perhaps by increasing the exposure of these antigens in affected 
tissues. Trough processes such as epitope spreading, isotype switching and cross-
reactivity this might after that develop into the co-expression of several antibodies 
as is often observed in RA patients. 
4.2.3 Presence of ACPAs in association with alcohol 
and BMI
In EIRA, anti-Cit-F4Cit-Cit antibody was negatively associated with being an ever-
drinker (OR=0.56, FDR=7.9%, 95% CI=0.37-0.85) while anti-Cit-F4R-Cit anti-
body indicated a suggestive association with being an ever-drinker (OR=1.56, 
p-value=0.046). The association of ACPAs and high consumption of alcohol also 
was investigated, and no significant association was detected. Merely a suggestive 
association between IgA-RF (OR=0.62, p-value=0.015) and anti-Cit-Fibα580-600 
(OR=1.83. p-value=0.016) and high alcohol consumption was observed. 
The association between the RA ACPA-specificity and BMI was also investigated 
in the EIRA. Anti-Cit-F4R-Cit antibody (OR=1.60, p-value=0.032) had a suggestive 
positive association with obesity taking BMI>30 while anti-Cit-Vim60-75 antibody 
(OR=0.65, p-value=0.011) showed a suggestive negative association with obe-
sity (though FDR>10%). Thereafter, the association between 22 antibodies and 
being overweight taking BMI>25 was tested; only a stronger negative sugges-
tive association was observed between the anti-Cit-Vim60-75 antibody (OR=0.71, 
p-value=0.0049, FDR=11%) and being overweight. 
Previous studies has shown alcohol consumption (89, 90) have a significant 
inverse association with risk of RA (89-93) while a higher body mass index is 
associated with increased risk of only ACPA negative RA (93-95). Since in this 
thesis, the focus was to assess the effect of environmental risk factors on ACPA 
fine-specificity, so it might be anticipated to observe no association between BMI 
and these antibodies. Our results indicated the contribution of alcohol consumption 
and BMI in the development of RA is not through the pathways involving ACPAs.
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5 METHODOLOGICAL CONSIDERATION 
Several strengths and limitations of the studies included in this thesis deserve to 
be mentioned:
5.1 STRENGTHS 
The main strength of population-based studies included in this thesis, the SHEEP, 
the EIRA, the IMPROVE and the eRA-Umeå , is using the large number of indi-
viduals who have provided a wide range of information in lifestyle, environmental 
factors and biological tests at the time of recruitment in the study. Besides, the 
participation proportion of cases in all case-control and cohort studies included in 
this thesis were high, which allows the participants in the study to be representa-
tive of the study base.
Furthermore, the combination of two population of EIRA and eRA-Umeå pro-
vided a larger sample size and increased the power of association analysis, how-
ever, more in-vitro and epidemiological investigations on a larger population are 
required to draw a particular conclusion on the association between smoking and 
RA-specific antibodies. 
Applying united and standard methods to measure exposure and outcome was one 
of the most important strengths of all four populations. c-IMT measurements were 
performed in all seven centers of IMPROVE using the same protocol on high-
resolution B-mode ultrasound. In EIRA and eRA-Umeå also similar customized 
microarray were used to measure reactivity towards citrullinated peptides. 
Another strength of IMPROVE that worth to mention is using custom made 
CardioMetaboChip and ImmunoChip collect the genetic data that increased 
the probability of finding SNPs associated with CV and inflammatory diseases. 
Moreover, in study III, when many concurrent statistical tests were involved in 
association analysis, to reduce the risk of detecting false-positive associations, the 
multiple-testing correction has been calculated (FDR).
5.2 CAUSALITY AND REVERSE CAUSALITY
To eventuate on a causal relationship between an exposure and outcome, the 
exposure sampling must be performed before outcome occurrence. In the SHEEP 
study, the serum of participants was collected minimum three months post-MI. 
The reason for late sampling was to wait for regaining stability in metabolic and 
inflammatory markers that caused by MI, and to avoid the influence of disease 
and medication on serum values. Hence, concluding on the causal relationship 
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between exposure and disease of the study I is not straight forward. There is a 
probability that measured biomarkers three months after MI not reflecting fully 
the true values before MI (140, 141). Although, there are some studies emphasiz-
ing on regaining metabolic stability three months after MI (140, 141). In addition, 
from a prospective study of other inflammatory biomarkers (IL-6 and TNF-α) in 
the SHEEP indicated comparable levels to baseline (39, 142, 143). Therefore, 
computed OR might be overestimated or underestimated, which cannot be cor-
rected in association analysis.
There is also a possibility that cases change their lifestyle habits after having a 
heart attack like post-MI smoking cessation and physical activity, which may 
affect measured biomarkers circulation. Similarly, for EIRA and eRA-Umeå, 
where autoantibodies might have been present years before the diagnosis of RA, 
patients might have experienced symptoms that cause them to alter their lifestyles. 
It is not possible to determine if exposure precedes the outcome precisely. It is 
however very improbable that the presence of autoantibodies causes individuals 
to start smoking. Therefore, it is essential to keep in mind that retrospective data 
collection might be subjected to inherent bias. In addition, it is unachievable to 
get a deep intuitive comprehending of the biological mechanisms underlying the 
observed association in observational studies. The evidence of the casual effect 
of sgp130 on atherosclerosis in the IMPROVE was inconclusive. 
Different source of errors in studies included in this thesis was discussed as follows.
5.3 MISCLASIFICATION BIAS
5.3.1 Misclassification of exposure 
Recall bias 
There is a possibility of introducing recall bias when participants are asked to 
recall exposures, as is the case with data on environmental and metabolic factors 
by questionnaires in study III (EIRA and eRA-Umeå cohorts). However, the short 
duration between onset of the first symptom and diagnosis of the disease (median: 
195 days) as well as the short time between diagnosis and filling the question-
naire (within a year) in EIRA make recall bias less likely. Although data on main 
exposures in SHEEP and IMPROVE were not collected by questionnaires, infor-
mation on some of the covariates were self-reported, which may lead to potential 
misclassification of confounders. 
In general recall bias is an inherent restriction in all case-control study plans 
because there is a possibility that cases remember differently in comparison to 
controls when they answer the questionnaires. 
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Survival bias 
In study I, the results cannot be genuinely generalized to fatality cases (n= 603) 
since only non-fatal MI cases were included in the analysis. This was due to impos-
sibility of measuring biomarkers three months after the event in fatal cases. There 
is a possibility that measured exposure in non-fatal cases is different (might be 
lower) from the level of exposure in fatal cases. It would be therefore a possibility 
of underrating the effect of exposures (sIL-6R and sgp130) on the outcome (MI).
Biomarker measurements 
In all the four population, collected serum and DNA samples were kept in biobank 
-80°C to -70°C freezers for several years until experiments. It is a common pheno-
menon in biomarker epidemiological studies nowadays. Biomarkers concentrations 
are likely affected by the long storage and samples might degrade. According to 
prior epidemiological studies on cytokines using fresh samples in comparison with 
SHEEP and IMPROVE samples, the direction and size of the association is not 
massively affected by storage time (45, 144-147). However, if sample degrada-
tion occurs, it would lead to non-differential misclassification since neither the 
exposure nor the outcome would differentially alter in cases and controls in the 
SHEEP (and in all participants of the IMPROVE). 
Furthermore, the exposures were dichotomized taken in the analysis in the EIRA 
(presence or absence of the specific antibody) and in the SHEEP (sIL-6R and 
sgp130). Thus, non-differential misclassification of a dichotomous exposure is 
likely. If the continues values of exposure were used still the non-differential mis-
classification may change the OR, depending on in which strata the dichotomous 
exposure was misclassified. In addition, none of the studies aimed to establish on 
absolute values for the biomarkers in this thesis. One of the strategies to avoid 
misclassification of exposure in the SHEEP was to measure biomarkers in cases 
and controls blindly in every experiment. In the IMPROVE all ultrasonic scans 
also were read blindly by experts. 
5.3.2 Misclassification of outcome 
c-IMT is largely applied as surrogate marker for atherosclerosis, but still, it does 
not mirror the atherosclerosis alone. Thus, it is difficult to generalize the findings 
from c-IMT association in IMPROVE to atherosclerosis. However, several ultra-
sonic measurements were performed to obtain c-IMT variables, those that were 
selected (IMTmean, IMTmax, IMTmean-max) to be included in study II, were highly 
correlated to each other and thus yielded similar information.
The criteria for MI diagnosis have changed since the time of collecting SHEEP 
materials. The MIs included in the SHEEP might not be representative of all MIs 
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diagnosed with new criteria, considering more precise recent methods. Therefore, 
the results from the SHEEP might not be generalized to the more recent settings. 
In study III, the presence of antibodies was derived from the 98th percentile in the 
healthy controls. Given the low frequency of each antibody among the healthy 
controls (2% by definition) the selection of controls and chance will have a con-
siderable effect on the threshold value and consequently the frequency of the 
antibody among the cases. However, this process should be random and not lead 
to differential misclassification of outcome.
5.4 SELECTION BIAS
Non-participation is very important in the epidemiological studies and can be a 
source of selection bias when individuals participating in the study are different from 
non-participants. The participation rate was high in SHEEP, EIRA and eRA-Umeå 
cohorts, which gives a smaller chance of selection bias. If the exposure information 
differs among participants and non-participant, it might cause a differential non-
participation bias, which can underestimate the association result. In the SHEEP, 
there were individuals that had not enough serum samples for biomarkers measure-
ments (sIL-6R and sgp130). They were distributed amongst cases and controls 
at random, therefore, the selection bias is improbable. Furthermore, the baseline 
characteristics of excluded individuals were compared to the total population of 
the SHEEP. Most of the risk factors and anthropometric characteristics indicated 
comparable prevalence except prevalence of age and hypertension.
Individuals included in the IMPROVE were selected according to high-risk pro-
file for CVE, with the presence of at least three vascular risk factors, from seven 
European centers. Thus, the selected population for IMPROVE are not repre-
sentative of all population with European ethnicity at risk of CVD. Therefore, the 
results cannot be generalized to the general European population with less than 
three CV risk factors.
Cases in EIRA and eRA-Umeå were newly diagnosed included from all rheu-
matology units, from both public and private sectors. Due to the free health care 
system in Sweden, all individuals have access to medical services and would not 
avoid seeking medical care because of financial concerns. The fact that almost all 
public and private rheumatology units in the study area reporting the diagnosed 
RA patients to the EIRA database were linked to the general welfare system, 
therefore, reduces the chance of selection bias. However, investigations into non-
participation in EIRA using the 1996-2005 part of the cohort (patients in study III 
were recruited later) showed that non-participant cases were older, had a lower 
income, shorter education and were more often born outside of Sweden (148). 
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No similar investigations of the later part of the cohort have been performed, but 
it is likely that the participation bias is similar. It is unclear at this point if age, 
income, education or ethnicity affects the presence of the investigated antibodies. 
The revised diagnosis criteria of (EULAR/ACR) in 2010 included ACPA-antibodies 
as one criterion and enables the detection of patients earlier in their disease. Since 
both cohorts in study III were included based on the old 1987 diagnosis criteria, this 
might mean that the sample is slightly biased and includes a smaller proportion of 
ACPA positive patients. However, since patients usually express ACPA-antibodies 
several years before diagnosis, this bias is expected to be small. 
5.5 CONFOUNDING BIAS
Presence of confounders may change the estimated strength of the association. By 
definition, the confounder must have an association with both the disease and the 
exposure (104). The models need to be adjusted for confounders to avoid bias in 
the estimates of the parameters describing the association of interest. Therefore, in 
EIRA and eRA-Umeå, the smoking association analysis were adjusted for alcohol 
and alcohol association analysis for smoking (Figure 6). 
Figure 6. potential confounding effect of alcohol consumption in the associa-
tion between smoking and RA specific antibodies. Examples are hypothetical.
? Exposure 
Confounder 
Outcome 
Environmental risk factors, e.g. Smoking  
e.g. Alcohol
RA specific ACPA (Ab1-Ab22+RFs) 
In SHEEP and IMPROVE, the biomarkers associations analyses have been adjusted 
for conventional CV risk factors, e.g. smoking, diabetes, hypercholesterolemia 
and hypertension. However, in the study of genetic factors of IMPROVE, fewer 
potential confounders were considered because the exposure itself is quite improb-
able to be affected by other factors.
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5.5.1 Residual and unmeasured confounding 
It is rational when evaluating inflammatory biomarkers, they could also reflect 
inflammatory statuses, which were not the aim of investigation when the study 
was designed. Association of cytokines and their receptors with different cancers 
and other chronic inflammatory diseases have been reported (149, 150). It was not 
possible to adjust for these inflammatory conditions in study I and II since the data 
was not available. Therefore, it is difficult to rule out the presence of uncontrolled 
confounders in those studies.
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6 CONCLUSION AND FUTURE PERSPECTIVE
6.1 STUDY I, II
Increased serum level of sIL-6R had an association with increased risk of MI while 
the elevated serum level of sgp130 has an inverse association with the risk of MI, 
in a Swedish population aged 45-70 years old. A sign of interaction between sIL-
6R and sgp130 with risk of MI was detected. More extensive population-based 
studies are required to increase the power to derive a conclusion on the additive 
interaction. However, our results highlighted the necessity of focusing on molecu-
lar pathways instead of only one biomarker when estimating the risk of CVDs.
 Investigation of the SNPs associated with sgp130 serum level indicated a possi-
ble overlap on genetic variants regulating sgp130 level and c-IMT measures. Our 
results can shed light on several cardiometabolic pathways with the intervention 
of sgp130. Increasing the knowledge on genetic variants regulating sgp130 is 
important, to understand the mechanisms underlying generation of sgp130 as an 
inhibitor of IL-6 trans-signaling and as a potential therapeutic marker in inflamma-
tory diseases. Thus, replication of these findings and more investigation on thera-
peutic role of high sgp130 may be of interest for future atherosclerosis research.
6.2 STUDY III
A high co-occurrence exists among a group of RA-specific antibodies while some 
other antibodies are expressed in RA patients unaccompanied of each other. Smoking 
is associated with antibodies against IgA-RF and a limited set of citrullinated pep-
tides. This indicates that smoking might play a causal role in the development of 
RA through a mechanism involving antibodies reactivity towards these peptides. 
As a future perspective of ACPA studies, it will be of interest to assess the relation-
ship between smoking and IgA response to ACPA. Further investigations on the 
biological mechanism of the associations between smoking and anti-citrullination 
immunity are also needed.
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